On May 16, 2022 ITM Isotope Technologies Munich SE (ITM), a leading radiopharmaceutical biotech company, reported that it will host a scientific symposium on precision oncology titled "Targeted Radionuclide Therapy – present and future prospects" held as an ancillary event in parallel to the 2022 ASCO (Free ASCO Whitepaper) Annual Meeting (Press release, ITM Isotopen Technologien Munchen, MAY 16, 2022, View Source [SID1234614673]). The symposium will feature key opinion leaders in the field and will be held in a hybrid format on June 03, 2022 from 11:00 am – 12:30 pm CST in the Hyatt Regency McCormick Place, in Chicago, USA and online.
Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:
Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing
Schedule Your 30 min Free Demo!
Targeted Radionuclide Therapy is an approach to treating a variety of cancer types. As new areas of interest and advancing approaches to implementing this uniquely selective therapeutic modality continue to be highlighted, the session will offer an overview of the key topics. The panel will focus on the clinical application of Targeted Radionuclide Therapy in the treatment of neuroendocrine tumors, prostate cancer and potential future prospects. They will also spotlight the benefits and risks of this therapeutic approach, address any challenges that may be encountered, and provide valuable insights to their patient management experiences. Participants will be able to interact with the speakers in a Q&A session at the end of the event.
Scientific Program and Speakers:
Welcome and Introduction
Pamela Kunz, MD
Smilow Cancer Hospital and Yale Cancer Center
Clinical Application of Targeted Radionuclide Therapy in Neuroendocrine Tumors
Pamela Kunz, MD (20min)
Smilow Cancer Hospital and Yale Cancer Center, New Haven
Clinical Application of Targeted Radionuclide Therapy in Prostate Cancer
Michael Morris, MD (20 min)
Memorial Sloan Kettering Cancer Center, New York
Personalizing the Targeted Radionuclide Therapy, Advancements and Challenges
Thomas Hope, MD (20min)
University of California, San Francisco
The Future of Targeted Radionuclide Therapy
Wolfgang Weber, MD, PhD (20min)
Klinikum rechts der Isar (the University Hospital of the Technical University of Munich)
Discussion & Closing Remarks
Pamela Kunz, MD
For the full scientific program and registration form please click here:
View Source
The symposium will be recorded, and available on demand for 6 months after the event.
The event is not sponsored, endorsed, or accredited by ASCO (Free ASCO Whitepaper), CancerLinQ, or Conquer Cancer the ASCO (Free ASCO Whitepaper) Foundation.
About Targeted Radionuclide Therapy
Targeted Radionuclide Therapy is an emerging class of cancer therapeutics, which seeks to deliver radiation directly to the tumor while minimizing radiation exposure to normal tissue. Targeted radiopharmaceuticals are created by linking a therapeutic radioisotope to a targeting molecule (e.g., peptide, antibody, small molecule) that can precisely recognize tumor cells and bind to tumor-specific characteristics, like receptors on the tumor cell surface. As a result, the radioisotope accumulates at the tumor site and decays, releasing a small amount of ionizing radiation, thereby destroying tumor tissue. The highly precise localization enables targeted treatment with minimal impact to healthy surrounding tissue.